Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

102.63 -2.64 (-2.51%)
Official Closing Price Updated: 6:30 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
61 62 Next >
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
LLY stock struggles, falling 16.85% over the last month due to bearish technicals and political uncertainty. But with projected sales and earnings growth, could this be a buying opportunity? 
Via Benzinga
Are Diet Drug Companies Over The Hump?
Eli Lilly made a reversal bottom low on Monday after a gap lower. Today’s price action was confirmation. 
Via Talk Markets
Topics Stocks / Equities
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
PBMs Express Scripts, Caremark, and Optum challenge the FTC's administrative proceedings, arguing it violates constitutional rights and threatens the stability of drug pricing. 
Via Benzinga
Is Novo Nordisk Stock a Buy Right Now?
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares. 
Via The Motley Fool
Novo Nordisk Unusual Options Activity For November 19
Via Benzinga
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
Novo Nordisk launches Wegovy in China to address rising obesity rates, priced lower than in the U.S. Initial sales start at a Shanghai public hospital. 
Via Benzinga
This Is What Whales Are Betting On Novo Nordisk
Via Benzinga
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
Not-So-Big Pharma
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Mergers and acquisitions could make a comeback with Trump headed back to Washington. 
Via The Motley Fool
Topics Government
Exposures Political
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
To gain an edge, this is what you need to know today. 
Via Benzinga
While growth is established for NYSE:NVO, the stock's valuation remains reasonable.
Investors should take note ofNOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that remains attractively priced. 
Via Chartmill
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone density at the highest dose. 
Via Benzinga
What's Going On With Hims & Hers Health Stock On Wednesday?
Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing rising demand and pharmacy shortages. 
Via Benzinga
Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot
Shares were rattled Tuesday after a report showed its obesity treatment can cause lower bone mineral density. 
Via Investor's Business Daily
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access. Novo Nordisk's production shift raises concerns as diabetes cases rise,... 
Via Benzinga
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC's Jim Cramer suggested the news could... 
Via Benzinga
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
The company is testing MariTide as a monthly shot, rivaling weekly injections from Novo Nordisk and Eli Lilly. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Top Stocks Crushing Q3 Earnings With Strong 2024 Guidance
Hims & Hers, Payoneer, and Astera Labs lead Q3 earnings with standout revenue growth, forecast upgrades, and strategic wins—stocks to watch for growth potential 
Via MarketBeat
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the company. 
Via Benzinga
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
The good times aren't over, but the peak of the party might be passing. 
Via The Motley Fool
Is Viking Therapeutics a Buy on the Dip?
Viking stock has slipped more than 20% from its peak. 
Via The Motley Fool
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political
Investors Like Certainty. Trump's Win Gave Them Some.
We're also talking about Super Micro, Nvidia, and weight loss. 
Via The Motley Fool
Topics Government
Exposures Political
How Altimmune Could Grab a Big Chunk of the GLP-1 Market
Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users. 
Via MarketBeat
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including reports of deaths and hospitalizations, while working with the FDA to resolve... 
Via Benzinga
Topics Death
Exposures Death Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
61 62 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.